Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibiotic shows promise against Drug-Resistant lung bug

NCT ID NCT07372781

Disease control Sponsor: Beijing Chest Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new antibiotic called contezolid against a hard-to-treat lung infection caused by Mycobacterium abscessus. Twenty-four adults will take either contezolid or an older drug, linezolid, for 14 days. Researchers will measure how quickly the drug kills the bacteria in sputum samples to see if contezolid works as well or better than the current treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
contezolid (an antibiotic)
What this could lead to
If contezolid works better than linezolid, it could offer a new treatment option for hard-to-treat Mycobacterium abscessus lung infections.
What could go wrong
This is a small, early-phase trial with only 24 people. The drug may not prove effective or safe in larger studies. Side effects are possible, and the infection often requires long-term therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged between 18 and 65 years old; * Weight ranging from 40 kg to 90 kg; * At least one positive sputum culture for Mycobacterium abscessus within 6 months prior to screening, and one positive sputum culture for Mycobacterium abscessus with molecular species identification during the screening period within 1 month prior to the study; * Voluntary participation in this study and signing of the informed consent form; (5) Male and female participants must use effective contraception during the study and for 1 month after the study ends. Exclusion Criteria: * Patients who have been on long-term corticosteroid therapy or taking immunosuppressants within 90 days prior to screening; * Pregnant women, postpartum women, and lactating patients; * Patients with a history of bedaquiline allergy or known hypersensitivity, or a history of severe adverse reactions; * Patients with evidence of bedaquiline resistance; * Patients deemed unsuitable for participation in this study by the investigator's assessment; * Patients whom the investigator believes participation in this study would harm their health, or who are unlikely to comply with the scheduled visits and assessments as outlined in the protocol, and therefore are not suitable for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Monotherapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mycobacterial infectious disease Mycobacterium Infections, Nontuberculous

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Monotherapy Mycobacterium abscessus infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing chest hospital affiliated to Capital medical university, Beijing Tuberculosis & Thoracic Tumor Research Institute

    Beijing, Beijing Municipality, 101149, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.